Trial Profile

Partially-blind Immunogenicity and Safety Study of GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 08 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GSK 2321138A (Primary) ; Influenza virus vaccine
Indications Influenza virus infections
Focus Adverse reactions; Pharmacodynamics; Registrational
Sponsors GlaxoSmithKline

Most Recent Events

22 Nov 2012 Results were presented at the IDweek in October 2012, according to a GlaxoSmithKline media release.
22 Nov 2012 Primary endpoint 'Haemagglutin-inhibition-antibody-levels' has been met.
17 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com